Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

Mostrar otras versiones (1)

A main effector mechanism of rituximab (RTX) is the induction of complement-dependent cytotoxicity (CDC). However, this effector function is limited, because CLL cells are protected from complement-induced damage by regulators of complement activation (RCAs). A prominent RCA in fluid phase is factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hörl, S, Bánki, Z, Huber, G, Ejaz, A, Windisch, D, Muellauer, B, Willenbacher, E, Steurer, M, Stoiber, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826035/
https://www.ncbi.nlm.nih.gov/pubmed/23760402
http://dx.doi.org/10.1038/leu.2013.169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826035/
https://www.ncbi.nlm.nih.gov/pubmed/23760402
http://dx.doi.org/10.1038/leu.2013.169

Ejemplares similares